X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with SUVEN LIFE - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs SUVEN LIFE - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA SUVEN LIFE TORRENT PHARMA/
SUVEN LIFE
 
P/E (TTM) x 29.0 20.1 144.9% View Chart
P/BV x 5.5 3.7 148.4% View Chart
Dividend Yield % 1.0 1.0 97.9%  

Financials

 TORRENT PHARMA   SUVEN LIFE
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-17
SUVEN LIFE
Mar-16
TORRENT PHARMA/
SUVEN LIFE
5-Yr Chart
Click to enlarge
High Rs1,768339 522.2%   
Low Rs1,186144 821.1%   
Sales per share (Unadj.) Rs346.139.2 881.9%  
Earnings per share (Unadj.) Rs55.27.5 739.4%  
Cash flow per share (Unadj.) Rs73.38.8 835.4%  
Dividends per share (Unadj.) Rs14.002.00 700.0%  
Dividend yield (eoy) %0.90.8 114.5%  
Book value per share (Unadj.) Rs257.149.0 524.7%  
Shares outstanding (eoy) m169.22127.28 133.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.36.2 69.3%   
Avg P/E ratio x26.832.4 82.7%  
P/CF ratio (eoy) x20.127.5 73.2%  
Price / Book Value ratio x5.74.9 116.6%  
Dividend payout %25.426.8 94.7%   
Avg Mkt Cap Rs m249,88730,732 813.1%   
No. of employees `00011.81.0 1,234.9%   
Total wages/salary Rs m9,934416 2,385.7%   
Avg. sales/employee Rs Th4,971.55,236.1 94.9%   
Avg. wages/employee Rs Th843.2436.5 193.2%   
Avg. net profit/employee Rs Th792.4995.5 79.6%   
INCOME DATA
Net Sales Rs m58,5694,995 1,172.5%  
Other income Rs m2,233194 1,154.0%   
Total revenues Rs m60,8025,189 1,171.8%   
Gross profit Rs m13,7731,233 1,117.4%  
Depreciation Rs m3,069167 1,835.6%   
Interest Rs m2,05654 3,792.6%   
Profit before tax Rs m10,8811,205 903.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,545255 605.9%   
Profit after tax Rs m9,336950 983.0%  
Gross profit margin %23.524.7 95.3%  
Effective tax rate %14.221.2 67.1%   
Net profit margin %15.919.0 83.8%  
BALANCE SHEET DATA
Current assets Rs m53,8414,986 1,079.8%   
Current liabilities Rs m31,6121,042 3,033.1%   
Net working cap to sales %38.079.0 48.1%  
Current ratio x1.74.8 35.6%  
Inventory Days Days9761 159.3%  
Debtors Days Days8439 214.0%  
Net fixed assets Rs m42,0793,126 1,346.3%   
Share capital Rs m846127 664.7%   
"Free" reserves Rs m42,6553,717 1,147.4%   
Net worth Rs m43,5016,236 697.5%   
Long term debt Rs m22,408432 5,183.5%   
Total assets Rs m101,2508,079 1,253.2%  
Interest coverage x6.323.2 27.1%   
Debt to equity ratio x0.50.1 743.1%  
Sales to assets ratio x0.60.6 93.6%   
Return on assets %11.312.4 90.5%  
Return on equity %21.515.2 140.9%  
Return on capital %19.618.9 104.0%  
Exports to sales %087.5 0.0%   
Imports to sales %012.2 0.0%   
Exports (fob) Rs mNA4,371 0.0%   
Imports (cif) Rs mNA611 0.0%   
Fx inflow Rs m20,0664,666 430.0%   
Fx outflow Rs m5,304942 563.0%   
Net fx Rs m14,7623,724 396.4%   
CASH FLOW
From Operations Rs m10,127922 1,098.4%  
From Investments Rs m-7,869-619 1,270.6%  
From Financial Activity Rs m-1,918-698 274.6%  
Net Cashflow Rs m212-396 -53.4%  

Share Holding

Indian Promoters % 71.5 63.4 112.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 0.0 -  
FIIs % 12.6 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 36.5 24.1%  
Shareholders   26,511 37,287 71.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   ALKEM LABORATORIES  PLETHICO PHARMA  GLENMARK PHARMA  ABBOTT INDIA  FRESENIUS KABI ONCO.  

Compare TORRENT PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Of Global Markets Hitting Record Highs and Top Stocks in Action During the Week(RoundUp)

Global stock markets ended the week on a positive note. Benchmark indices in US grew by 1% during the week. The Down Jones Industrial Average topped the 26,000.

Related Views on News

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Jan 19, 2018 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 8-QTR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS